European cancer biomarker market is projected to grow at CAGR of 11.6% during the forecast period. The Europe is considered to be one of the dominating regions in the cancer biomarker market as it has a high healthcare expenditure and infrastructure. Major factor contributing to the cancer biomarker market are high prevalence of cancer, high per capita healthcare expenditure and high awareness towards cancer in the region. Unhealthy lifestyle such as smoking, consumption of drugs and alcohol in country are the major factors for the prevalence of cancer among men and women. Government’s initiatives, programs and funding for the cancer related programs are also contributing in the growth of cancer biomarker market in the region. In Europe, several key players are present which are driving the cancer biomarker market such as Agendia N.V., bioMérieux S.A., Novartis AG and QIAGEN N.V.
Visit for Global Cancer Biomarker Market Report at: https://www.omrglobal.com/industry-reports/cancer-biomarkers-market
In men, prostate cancer is the most common type of disease in Northern, Western and Southern European nations, while lung cancer is the most commonly diagnosed in Central and Eastern Europe. Lung growth is the main source of cancer for deaths among men in every European nation, while breast cancer is most common in women. Activities such as smoking, alcohol; consumption, inactivity, inadequate diet and other sources are some of the factors responsible for cancer, which creates scopes for the European cancer biomarker growth during the forecast period.
According to the International Association for the study of Lung cancer, the European teenager have a high susceptibility of smoking as that of rest of the world. This will eventually increase the incidence of lung cancer. In future lung cancer incidences and deaths will eventually rise in the European region. Hence the European cancer biomarker market will also increase.
Research Methodology
The market study of the European cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
1. European Cancer Biomarker Market Research and Analysis by Biomarker Type
2. European Cancer Biomarker Market Research and Analysis by Cancer Type
3. European Cancer Biomarker Market Research and Analysis by Application
4. European Cancer Biomarker Market Research and Analysis by Profiling Technology
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. European Cancer Biomarker Market by Biomarker Type
5.1.1. Genetic Biomarker
5.1.2. Protein Biomarker
5.2. European Cancer Biomarkers Market by Cancer Type
5.2.1. Lung Cancer
5.2.2. Prostate Cancer
5.2.3. Breast Cancer
5.2.4. Colorectal Cancer
5.2.5. Cervical Cancer
5.2.6. Other
5.3. European Cancer Biomarkers Market by Applications
5.3.1. Drug Discovery and Development
5.3.2. Diagnosis
5.3.3. Risk Assessment
5.3.4. Prognostics
5.4. European Cancer Biomarker Market by Profiling Technology
5.4.1. Omics Technology
5.4.2. Immunoassays
5.4.3. Cytogenetics
5.4.4. Bioinformatics
6. Regional Analysis
6.1. UK
6.2. Germany
6.3. Italy
6.4. France
6.5. Spain
6.6. Rest of Europe
7. Company Profiles
7.1. Abbott laboratories Inc.
7.2. Astellas Pharma Inc.
7.3. Becton, Dickson and Co.
7.4. Bio-Rad Laboratories, Inc.
7.5. Danaher Corp.
7.6. F. Hoffmann-La Roche Ltd.
7.7. Merck and Co., Inc.
7.8. Novartis AG
7.9. Pfizer Inc.
7.10. QIAGEN GmbH
7.11. Thermo Fisher Scientific Inc.
1. EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2018-2025 ($ MILLION)
2. EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
3. EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
4. EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY PROFILING TECHNOLOGY, 2018-2025 ($ MILLION)
5. EUROPEAN CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
1. EUROPEAN CANCER BIOMARKER MARKET SHARE BY BIOMARKER TYPE, 2018 VS 2025 (%)
2. EUROPEAN CANCER BIOMARKER MARKET SHARE BY CANCER TYPE, 2018 VS 2025 (%)
3. EUROPEAN CANCER BIOMARKER MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
4. EUROPEAN CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY, 2018 VS 2025 (%)
5. EUROPEAN CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
6. UK CANCER BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)